Year
DEALS // DEV.
Country
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target
Lead Product(s) : Hydroxyurea
Therapeutic Area : Hematology
Study Phase : Approved FDF
Sponsor : Norgine
Deal Size : Undisclosed
Deal Type : Acquisition
Norgine Strengthens Rare Disease Portfolio with Acquisition of Theravia
Details : Through the acquisition, Norgine will have six core products in its rare disease portfolio, which includes Siklos (hydroxyurea) is being indicated for the treatment of sickle cell anemia.
Product Name : Siklos
Product Type : Cytotoxic Drug
Upfront Cash : Undisclosed
April 15, 2025
Lead Product(s) : Hydroxyurea
Therapeutic Area : Hematology
Highest Development Status : Approved FDF
Sponsor : Norgine
Deal Size : Undisclosed
Deal Type : Acquisition